Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Looks To Erode Competitors’ Convenience Advantage With BCMA Bispecific

Dec 15 2023

• By Alaric DeArment

J&J's booth at ASH 2023 • Source: Scrip

Related Content

BMS Forges Ahead With Next Round Of Multiple Myeloma Therapies

Dec 14 2023

Regeneron Releases New Linvoseltamab Analysis As It Inches Toward ASH, Regulatory Filing

Dec 07 2023

Pfizer Touts Elrexfio’s Potential For Community Oncology Use In Myeloma

Aug 15 2023

J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval

Oct 26 2022

Related Companies

Johnson & Johnson

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Additional Topics

ImmunoOncology Business Strategies Commercial Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window